Pharmaceutical

Cidara buys back rights to flu therapy from J&J for $85m

Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.

Apr 27, 2024 - 00:00
Cidara buys back rights to flu therapy from J&J for $85m
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
Read the original article

Tags:

Previous Article

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Next Article

Lower dose of mpox vaccine is safe and generates six-week antibody response equi...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MBX-1416 by MBX Biosciences Inc for Hypoglycemia: Likel...

Nov 4, 2023

Opinion: Every senator should fill out a legislative advance directive

Opinion: Every senator should fill out a legislative ad...

Aug 29, 2023

Juul agrees to pay $462 million to 6 states and D.C., and to share documents

Juul agrees to pay $462 million to 6 states and D.C., a...

Apr 13, 2023